INTRODUCTION

44
Probiotics are defined by the Food and Agriculture Organization (FAO) of the United Nations 45
World Health Organization (WHO) as: "live micro-organisms which, when administered in 46 adequate amounts, confer health benefits on the host" (1). Their use is more and more popular 47 using trypan blue and spread on 24-well plates at 1X10 6 cells/well. Bacteria were added in 142 triplicate at a multiplicity of infection (MOI) of 1:10 in 20 µl PBS in a total volume of 1 ml 143 and plates were incubated for 24 h at 37°C in 10% CO 2 . Samples were finally stored at -80°C 144 until further analysis of IL-10 and IL-12p70 concentrations by ELISA (Mabtech, Sweden). 145
Mice. Specific pathogen-free BALB/c mice (females, 6 weeks of age; Janvier, France) 146
were maintained under normal husbandry conditions in the animal facilities of the National 147 Groups of mice (n=8) were daily administered intra-gastrically with 1X10 9 CFU of 168 each strain suspended in 200 µl of PBS (with a feeding needle) 10 days before virus challenge 169 and 10 or 14 days after. PBS was used as a negative control. Mice were monitored daily for 170 mortality, weight loss and visual score by scientists blinded to the study. For visual score, we 171 used a five-point scale previously published (24): 5. Healthy (no clinical symptoms); 4. Mild 172 (fur slightly ruffled); 3. Moderate (fur moderately ruffled and lethargy); 2. Severe (fur 173 severely ruffled and thin); 1. Very severe (no reaction to the stimulation). 174
Sample collection. On days 10 and 14 post infection, blood samples were obtained 175 from the retro-orbital venous plexus, centrifuged and sera stored at -80°C until further 176 analysis. Mice were then sacrificed by cervical dislocation and bronchoalveolar lavage fluid 177 (BALF) collected. To recover BALF, a catheter was tied into the exposed trachea and a 178 hypodermic needle and syringe was attached and used to inject and withdraw the lungs with a 179 total volume of 1 ml of PBS. BALF samples were stored at -80°C until further analysis. 180
Furthermore, lungs were collected for virus titration and stored at -80°C until analysis. 181 Viral quantification in mice lungs. Total RNA was isolated using Qiagen RNeasy 182 mini kit (Qiagen, France). Reverse transcription was carried out with a Superscript II reverse 183 transcriptase (Invitrogen, France) and the specific IAV M1 primer (21): 59-TCT AAC CGA 184 GGT CGA AAC GTA-39 following supplier's recommendations. Viral titers were quantified 185 using quantitative PCR. We used the specific IAV M1 primer: 59-TCT AAC CGA GGT 186 CGA AAC GTA-39 and the Mastercycler realplex (Eppendorf, France). The PCR condition 187 and cycle were as follows: initial DNA denaturation 10 min at 95°C, followed by 40 cycles 188 
RESULTS
201
In vitro screening of the strain collection. Our bacterial strain collection was first 202 analyzed in a stress resistance experiment. As shown in Fig. 1 LGG positive control strains (data not shown). 240
These promising results, demonstrate a tendency of L. plantarum CNRZ1997 strain to 241 decrease the body weight loss after infection with a high dose of IAV (i.e. 2000 PFU/mouse). 242
We then decided to test the probiotic effects of CNRZ1997 strain with a lower dose of IAV 243 (100 PFU/mouse). This lower viral dose was used to induce moderate symptoms in mice 244 which can be significantly counterbalanced by our candidate probiotic bacterium. 245 PBS-treated and infected mice displayed a weight loss of ~30% (at day 10) when 246 compared to healthy control mice when mice treated with the pro-inflammatory L. plantarum 247 CNRZ1997 strain displayed only a reduction in weight loss of ~10% of body weight (at day 248 10). In addition, weight loss was delayed in CNRZ1997-treated mice over the time course of 249 the assay and an earlier initiation of recovery was also observed when compared to PBS-250 treated mice (data not shown). These results were confirmed by AUWC analysis (Fig. 6B) . 251
To better characterize the beneficial effects of CNRZ1997 strain in the murine model 252 of IAV infection, we used a five-point scale of visual score. At day 0 the 3 groups of mice 253 showed a score of 5 (Fig. 7A) . At day 10, PBS-treated and infected mice present a score of 3 254 (moderate symptoms) while mice treated with CNRZ1997 strain showed a score of ~4. 255
Influenza virus titers in infected mice. Viral titration in the lungs of infected mice 256 revealed CNRZ1997-treated mice present a lower viral titer than infected control mice at days 257 10 and 14 post-infection (Fig 7B) . Although, at day 10 no significant difference was observed 258 in virus load between control mice and mice receiving the CNRZ 1997 strain, this difference 259 becomes significant at day 14. In this study, we determine the immunomodulatory properties of 158 strains of LAB in 269 order to identify the most interesting candidate probiotic strain able to alleviate the RVI 270 symptoms. For this, we first performed a large scale screening of the 158 strains for their 271 resistance to bile salts. Indeed, bile salts may constitute a deleterious factor preventing a given 272 strain to exert its beneficial properties in vivo. A high-throughput method was used to rapidly 273 characterize strains resistance. Among the tested strains, L. plantarum CNRZ1997 had a delay 274 of 2.9 h. Eighty strains (62.5 % of the collection), including VEL12208 and VEL12195, 275
showed moderate resistance with a growth delay between 5 and 13 h. Eight strains were not 276 resistant to bile salts. This simple yet robust protocol could also be used to test other 277 properties such as other stresses or ability to grow in specific conditions. 278
The immunomodulatory effects of the bacterial collection were then assessed using 279 two cellular models: TNF-alpha activated HT-29 and PBMCs. These in vitro cellular models 280 are commonly used to validate the immunomodulatory properties (anti-or pro-inflammatory 281 cytokine profile) of a given candidate bacterium before validation in animal models. observations. Indeed, this strain was effective in preventing body weight loss (Fig. 6B) and 306 clinical condition alteration by alleviating significantly the symptoms of the infected mice 307 (Fig. 7A, p<0.05 In this work we decided to use LGG and DN114-001 strains as positive control in our 318 model of AIV, since they have already been successfully studied for its anti-AIV properties in 319 pre-clinical trials (23) and in a human clinical trial against RVI (13). Interestingly, the AUWC 320 results observed in mice treated with either LGG or DN 114-001 showed that there are no 321 protective effects of these two well-known probiotic strains in our IAV model. These 322 unexpected results can be explained by the fact that LGG strain was reported as protective 323 against IAV in mice after "intranasal" administration in contrast with our study where we 324 used an "intragrastric" route. In order to confirm this, we performed experiments using LGG 325 by intranasal route in our AIV model, and we confirmed a protective effect, however we 326 cannot favor this route since the aim of this study is to develop a probiotic oral dietary 327 supplement. Secondly, most trials using DN114-001 strain against AIV have been done with 328 the fermented final product (it means that it contains the L. casei DN114-001 strain combined 329 with two cultures commonly used in yogurt, Streptococcus thermophilus and Lactobacillus 330 bulgaricus) while in our study we used DN114-001 as a single isolated strain, so we cannot 331 discard a synergistic effect of DN114-001 strain and the fermented final product. 
